Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P62879
UPID:
GBB2_HUMAN
Alternative names:
G protein subunit beta-2; Transducin beta chain 2
Alternative UPACC:
P62879; B3KPU1; P11016; P54312
Background:
The Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2, also known as G protein subunit beta-2 or Transducin beta chain 2, plays a pivotal role in cellular signaling. It acts as a modulator or transducer in various transmembrane signaling systems, requiring the beta and gamma chains for GTPase activity, GDP-GTP exchange, and G protein-effector interaction.
Therapeutic significance:
Linked to Neurodevelopmental disorder with hypotonia and dysmorphic facies and Sick sinus syndrome 4, understanding the role of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 could open doors to potential therapeutic strategies.